Lipid Sciences Ends Enrollment in HDL Therapy Trial
Posted on: Friday, 21 December 2007, 03:00 CST
Lipid Sciences has concluded enrollment of new patients in the company's HDL therapy clinical trial currently being conducted at the Washington Hospital Center, Suburban Hospital, and Washington Adventist Hospital.
The participants in this clinical trial were randomized 1:1 in the treatment and placebo arms of the study titled, "randomized, single-blind, placebo-controlled study to evaluate the safety of the Lipid Sciences' selective delipidation system, PDS-2, in subjects with acute coronary syndrome (ACS)." Patients currently enrolled in the trial will have completed their scheduled plasma collection and re-infusion treatments by the end of January 2008.
Dr Lewis Meyer, president and CEO of Lipid Sciences, said: "The FDA approved protocol for this study permitted Lipid Sciences to enroll a maximum of 30 patients based on the expectation that there would be a drop-out rate of up to 33%. The unusually high retention rate of 92% that we have experienced in this trial has allowed the company to gather sufficient data based upon the current enrollment of 28 patients."
Source: Datamonitor
Related Articles
- Patient Safety in Hospitals Shows Five Consecutive Years of Improvement, According to Thomson Healthcare Study
- Community Blood Centers Hosting Toy Drive For Pediatric Patients at Area Hospitals
- Data393 Raises $22,000 to Benefit Former Patients of Craig Hospital
- SinoFresh Reports Patient Case Study: Allergic Fungal Rhinosinusitis in Adult Male With History of Sinus Conditions
- Covalent Group, Inc. Signs $2.2 Million Contract With New Sponsor to Conduct Clinical Trial in Patients With Cardiovascular Disease
- IDM Closes Enrollment to Its EP-2101 Therapeutic Vaccine Trial in Patients With Non-Small Cell Lung Cancer
- J.D. Power and Associates Reports: Reputation Plays a Vital Role in Influencing a Patient's Choice of Hospital
- One in Six Patients Discharged From Hospitals Needs Help to Prevent Potential Complications and Readmission
- Genentech Stops Enrolling Patients in Study
- Vitamin E Scare Hurts Cancer Trial; Doctors Say Their Study on Supplement, Prostate Cancer Prevention is Safe
 |
 |
User Comments (0)
RSS Feeds